Extendicare (TSX:EXE) Beta: 1.5740 (As of Jun. 24, 2026)


TSX:EXE Extendicare Inc TSX:EXE
81 GF Score
Price C$34.13
GF Value C$13.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Extendicare Beta?

Extendicare TSX:EXE +0.23% 81 Beta is 1.5740 as of Jun. 24, 2026. GuruFocus rates TSX:EXE with a GF Score™ of 81/100 and a GF Value™ of C$13.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Extendicare's Beta is 1.5740.


Extendicare  (TSX:EXE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Extendicare Beta Related Terms


Extendicare Beta Historical Data

* Premium members only.

The historical data trend for Extendicare's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Extendicare Beta Chart

Extendicare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.51 1.32 1.02 1.04 1.15

Extendicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.93 0.89 1.15 1.18

TSX:EXE vs HCA, THC, DVA: Beta Comparison

For the Medical Care Facilities subindustry, Extendicare's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Extendicare Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Extendicare's Beta distribution charts can be found below:

* The bar in red indicates where Extendicare's Beta falls into.


TSX:EXE
81GF Score
Extendicare Inc TSX:EXE
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Extendicare Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.5740 mean?
Extendicare (TSX:EXE) has a Beta of 1.5740 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Extendicare and its competitors.
Is Extendicare's Beta too high?
Extendicare's current Beta is 1.5740. Overall, Extendicare has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Extendicare's Beta compare to HCA and THC?
Extendicare's Beta of 1.5740 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Extendicare and its competitors. Extendicare's current Beta is 1.5740. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Extendicare stock overvalued right now?
Based on GuruFocus' analysis, Extendicare (TSX:EXE) is currently considered Significantly Overvalued. The stock's GF Value™ is C$13.93, compared to a current price of C$34.13 — trading 145% above its estimated fair value. The current Beta is 1.5740. Extendicare's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Extendicare (TSX:EXE), the current Beta is 1.5740 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Extendicare (TSX:EXE) Overvalued in 2026?

Based on GuruFocus' analysis, Extendicare stock appears to be overvalued. The current stock price of C$34.13 is trading 145% above its estimated GF Value™ of C$13.93. GuruFocus considers Extendicare to be Significantly Overvalued.

Key valuation signals for TSX:EXE:

  • Beta: 1.5740
  • GF Value™: C$13.93 vs. price of C$34.13 (145% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the TSX:EXE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Extendicare Business Description

Other Exchanges EXETF:USA0S9E:UK5XE:Germany
Address 3000 Steeles Avenue East, Suite 400, Markham, ON, CAN, L3R 4T9
Extendicare Inc is a senior care provider in Canada, focused on long-term care and home health care. The has three main business segments: Long-term Care (LTC), Home Health Care, and Managed Services. The Long-term Care segment, operating under the Extendicare brand, represents 53 owned homes in Ontario, Alberta and Manitoba. The Home Health Care segment, operating under the ParaMed brand, provides home health care services annually in Ontario, Alberta, Manitoba and Nova Scotia. The Managed Services segment, operating under the Extendicare Assist and SGP Purchasing Partner Network brands, provides management, consulting and group purchasing services to other care providers across Canada. The majority of the company's revenue is derived from the Long-term Care segment.
81GF Score

Get the complete analysis for TSX:EXE

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$34.13
Price
C$13.93
GF Value